William Blair Comments on Incyte’s Q2 Earnings (NASDAQ:INCY)

Incyte Co. (NASDAQ:INCY) – Investment analysts at William Blair lifted their Q2 2025 earnings estimates for shares of Incyte in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $1.11 per share for the quarter, up from their previous estimate of $1.10. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share. William Blair also issued estimates for Incyte’s Q3 2025 earnings at $1.19 EPS and Q3 2026 earnings at $1.30 EPS.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of Incyte from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Wells Fargo & Company increased their target price on shares of Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday, December 19th. Stifel Nicolaus increased their target price on shares of Incyte from $75.00 to $77.00 and gave the company a “hold” rating in a research report on Monday, February 10th. JMP Securities reissued a “market perform” rating on shares of Incyte in a research report on Tuesday, February 11th. Finally, UBS Group began coverage on shares of Incyte in a research report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 target price for the company. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $75.13.

Incyte Price Performance

Shares of INCY opened at $60.34 on Thursday. The company has a 50 day moving average price of $71.03 and a 200-day moving average price of $70.20. Incyte has a fifty-two week low of $50.35 and a fifty-two week high of $83.95. The stock has a market capitalization of $11.68 billion, a PE ratio of 223.49, a PEG ratio of 0.41 and a beta of 0.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%.

Insiders Place Their Bets

In related news, EVP Sheila A. Denton sold 14,069 shares of Incyte stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total value of $1,042,090.83. Following the completion of the transaction, the executive vice president now owns 25,848 shares in the company, valued at approximately $1,914,561.36. The trade was a 35.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the completion of the transaction, the executive vice president now owns 33,567 shares of the company’s stock, valued at $2,272,150.23. This trade represents a 37.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,827 shares of company stock valued at $3,322,618 over the last ninety days. Company insiders own 17.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CWA Asset Management Group LLC acquired a new position in Incyte during the 4th quarter worth approximately $1,933,000. Orion Portfolio Solutions LLC acquired a new position in shares of Incyte in the 3rd quarter valued at $770,000. Tri Ri Asset Management Corp acquired a new position in shares of Incyte in the 3rd quarter valued at $3,292,000. Cypress Capital Group acquired a new position in shares of Incyte in the 3rd quarter valued at $971,000. Finally, Bridgewater Associates LP boosted its holdings in shares of Incyte by 142.8% in the 3rd quarter. Bridgewater Associates LP now owns 308,632 shares of the biopharmaceutical company’s stock valued at $20,401,000 after buying an additional 181,504 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.